Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb;97(2):169-79.
doi: 10.1016/j.antiviral.2012.12.002. Epub 2012 Dec 10.

Experimental therapies for yellow fever

Justin G Julander  1
Affiliations
Review

Experimental therapies for yellow fever

Justin G Julander. Antiviral Res. 2013 Feb.

Abstract

A number of viruses in the family Flaviviridae are the focus of efforts to develop effective antiviral therapies. Success has been achieved with inhibitors for the treatment of hepatitis C, and there is interest in clinical trials of drugs against dengue fever. Antiviral therapies have also been evaluated in patients with Japanese encephalitis and West Nile encephalitis. However, no treatment has been developed against the prototype flavivirus, yellow fever virus (YFV). Despite the availability of the live, attenuated 17D vaccine, thousands of cases of YF continue to occur each year in Africa and South America, with a significant mortality rate. In addition, a small number of vaccinees develop severe systemic infections with the 17D virus. This paper reviews current efforts to develop antiviral therapies, either directly targeting the virus or blocking detrimental host responses to infection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A graphical representation of the flavivirus genome. The structural capsid (C), premembrane (prM), and envelope proteins are situated at the 5′ end of the translated region. The nonstructural (NS) proteins 1, 2A, 2B, 3, 4A, 4B, and 5 are located at the 3′ end of the genome. The 3′ and 5′ terminal ends possess untranslated regions (UTR) that are important for replication. The 5′ end possesses a cap structure. Arrowheads represent host protease cleavage sites, while diamonds represent viral protease cleavage sites. Known functions of the various viral proteins are also included.
Figure 2
Figure 2
Replication strategy of the flaviviruses, including YFV. The virus enters the cell by endocytosis and the viral RNA is released following fusion with an endosome. Viral RNA is translated by host ribosomes into a single polyprotein that is processed by host and virus-encoded proteases. The nonstructural proteins are involved in replication of the viral RNA. Viral RNA and structural proteins are packaged together into progeny virions, which bud from internal membranes before being released from the cell. “Lightning bolts” indicate potential targets for antiviral intervention; details of each target are contained in the text.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Anwar A, Hosoya T, Leong KM, Onogi H, Okuno Y, Hiramatsu T, Koyama H, Suzuki M, Hagiwara M, Garcia-Blanco MA. The kinase inhibitor SFV785 dislocates dengue virus envelope protein from the replication complex and blocks virus assembly. PloS one. 2011;6:e23246. - PMC - PubMed
    1. Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, Diamond MS, Atkinson JP. Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. The Journal of experimental medicine. 2010;207:793–806. - PMC - PubMed
    1. Avirutnan P, Hauhart RE, Somnuke P, Blom AM, Diamond MS, Atkinson JP. Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. Journal of immunology. 2011;187:424–433. - PMC - PubMed
    1. Barrett AD, Teuwen DE. Yellow fever vaccine - how does it work and why do rare cases of serious adverse events take place? Current opinion in immunology. 2009;21:308–313. - PubMed
    1. Beigel JH, Nordstrom JL, Pillemer SR, Roncal C, Goldwater DR, Li H, Holland PC, Johnson S, Stein K, Koenig S. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus. Antimicrobial agents and chemotherapy. 2010;54:2431–2436. - PMC - PubMed

LinkOut - more resources